Department of Rheumatology, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Department of Internal Medicine, Alzahra Hospital, Isfahan University of Medical Sciences, Isfahan, Iran.
Clin Rheumatol. 2018 Apr;37(4):955-962. doi: 10.1007/s10067-017-3949-2. Epub 2017 Dec 18.
This study was conducted to assess the ability of the British Isles Lupus Assessment Group-2004 (BILAG-2004), the SLE Disease Activity Index-2K (SLEDAI-2K), the European Consensus Lupus Activity Measurement (ECLAM), and the Revised Systemic Lupus Activity Measure (SLAM-R) to detect the need to treatment change in daily clinical practice. One hundred and two patients with SLE were enrolled and followed up for 2 to 8 months and visited at least 3 times. Physician Global Assessment, BILAG-2004, SLEDAI-2K, SLAM-R, and ECLAM, were calculated in every visit. Treatment change, dependent variable, was categorized as decrease/no change vs. increase. The aforementioned indices, independent variables, were compared to learn their ability in predicting the treatment change. The probability of treatment change was measured by generalized linear-mixed effect model (GLMM) and generalized estimating equations (GEE). Adjusted odds ratios were calculated. Predictive power of indices was compared by area under the curve (AUC) in plots of sensitivity vs. 1-specificity and application of receiver operating characteristic curves (ROC). BILAG-2004 and SLEDAI-2K had substantial correlation with treatment change. Among different GLMM models, BILAG-2004 followed by SLEDAI-2K showed the highest associations with treatment change. Among various GEE models, similar findings were observed. Also, these 2 indices had the highest sensitivity (the largest AUC) towards treatment change; BILAG-2004 (AUC = 0.779, 95% CI = 0.710-0.848, p = 0.001) and SLEDAI-2K (AUC = 0.771, 95% CI = 0.698-0.843, p = 0.001). BILAG-2004 followed by SLEDAI-2K had the highest predictability of treatment change.
这项研究旨在评估英国狼疮评估组-2004 年版(BILAG-2004)、系统性红斑狼疮疾病活动指数-2000 年版(SLEDAI-2K)、欧洲共识狼疮活动测量(ECLAM)和修订后的系统性红斑狼疮活动度量(SLAM-R)在日常临床实践中检测治疗需要改变的能力。共纳入 102 例 SLE 患者,随访 2-8 个月,至少就诊 3 次。每次就诊均计算医生总体评估、BILAG-2004、SLEDAI-2K、SLAM-R 和 ECLAM。将治疗改变(因变量)分为减少/不变与增加。将上述指标(自变量)与治疗改变进行比较,以了解它们预测治疗改变的能力。采用广义线性混合效应模型(GLMM)和广义估计方程(GEE)测量治疗改变的概率。计算调整后的比值比。通过绘制敏感性与 1 特异性的关系图和应用受试者工作特征曲线(ROC)比较指数的预测能力。BILAG-2004 和 SLEDAI-2K 与治疗改变有显著相关性。在不同的 GLMM 模型中,BILAG-2004 紧随其后的是 SLEDAI-2K 与治疗改变的关联度最高。在各种 GEE 模型中也观察到了类似的发现。此外,这两个指数对治疗改变的敏感性最高(AUC 最大);BILAG-2004(AUC=0.779,95%CI=0.710-0.848,p=0.001)和 SLEDAI-2K(AUC=0.771,95%CI=0.698-0.843,p=0.001)。BILAG-2004 紧随其后的是 SLEDAI-2K 对治疗改变的预测能力最高。